Chiusura precedente | 18,31 |
Aperto | 0,00 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 0,00 - 0,00 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 18.777 |
Capitalizzazione | 1,351B |
Beta (5 anni mensile) | 0,36 |
Rapporto PE (ttm) | 19,72 |
EPS (ttm) | 0,93 |
Prossima data utili | 01 ago 2024 |
Rendimento e dividendo (futuro) | 0,25 (1,57%) |
Data ex dividendo | 15 mag 2023 |
Stima target 1A | N/D |
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 million Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2023. Key Highlights Solid revenue growth continues with 10.6% reported growth (13.9% at CER) and 10.2% organic growth (13.4% at CER) to €191.4 millionSustained
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 September 2023 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period, from 18 September 2023 through 19 September 2023, Fagron purchased 17,266 of its owns shares at an average price of €16.12 per share corresponding to a total amount of €277,612.81. A total of 138,372 Fagron shares have been repurchased under the buy-back program at an averag
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 11 September 2023 through 15 September 2023, Fagron purchased 27,000 of its owns shares at an average price of €16.81 per share corresponding to a total amount of €453,745.66. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron’s obligations under its long term incentive scheme, which was ann